Sapacitabine
Showing 1 - 8 of 8
Breast Cancer Trial in Boston, Cambridge (Sapacitabine, Olaparib)
Active, not recruiting
- Breast Cancer
- Sapacitabine
- Olaparib
-
Boston, Massachusetts
- +1 more
May 2, 2022
Acute Myeloid Leukemia Trial in United States (Sapacitabine, Arm A, Sapacitabine, Arm B, Sapacitabine, Arm C)
Completed
- Acute Myeloid Leukemia
- Sapacitabine, Arm A
- +8 more
-
Birmingham, Alabama
- +14 more
Mar 23, 2022
Advanced Solid Tumors Trial in Boston (sapacitabine and seliciclib)
Completed
- Advanced Solid Tumors
- sapacitabine and seliciclib
-
Boston, Massachusetts
- +1 more
Dec 7, 2021
Leukemias, MDS Trial in Houston (sapacitabine)
Completed
- Leukemias
- Myelodysplastic Syndromes
- sapacitabine
-
Houston, TexasThe University of Texas MD Anderson Cancer Center
Dec 7, 2021
NSCLC Trial in Chicago, Hershey (sapacitabine)
Terminated
- Non-small Cell Lung Cancer
- sapacitabine
-
Chicago, Illinois
- +1 more
Dec 7, 2021
Cutaneous T-cell Lymphoma (CTCL) Trial in Stanford, Chicago, Houston (Sapacitabine)
Terminated
- Cutaneous T-cell Lymphoma (CTCL)
- Sapacitabine
-
Stanford, California
- +2 more
Dec 7, 2021
Leukemia Trial in Houston (Cyclophosphamide, Rituximab, Sapacitabine)
Terminated
- Leukemia
- Cyclophosphamide
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Aug 15, 2019
Acute Myeloid Leukemia, MDS Trial in Chicago, Buffalo, Houston (sapacitabine and decitabine (Part 1 - completed), sapacitabine
Unknown status
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- sapacitabine and decitabine (Part 1 - completed)
- sapacitabine and venetoclax (Part 2 - recruiting)
-
Chicago, Illinois
- +2 more
Jul 12, 2019